M&A Deal Summary |
|
|---|---|
| Date | 2011-03-14 |
| Target | Janssen Pharmaceuticals - Animal Health Business |
| Sector | Life Science |
| Buyer(s) | Elanco |
| Sellers(s) | Janssen Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1954 |
| Sector | Life Science |
| Employees | 9,000 |
| Revenue | 4.4B USD (2024) |
Elanco develops and markets products and services to improve animal health and protein production in more than 75 countries. Elanco was incorporated in 1954 and is based in Greenfield, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 11 |
| Sector: Life Science M&A | 1 of 7 |
| Type: Divestiture M&A Deals | 3 of 5 |
| Country: Belgium M&A | 1 of 1 |
| Year: 2011 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-08-20 |
Posilac
United States Posilac (rbST) is approved by numerous regulatory authorities worldwide to help dairy farmers improve milk productivity. BST (bovine somatotropin) is a natural protein produced in all cattle, helping adult cows produce milk. Milk from cows receiving Posilac is unchanged from milk from cows not receiving this supplement. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-01-24 |
Chemgen
Gaithersburg, Maryland, United States ChemGen Corp. is a bioscience company specializing in the development and commercialization of innovative feed enzyme products that improve the efficiency of poultry, egg, and meat production. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1973 |
| Sector | Life Science |
Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 3 |
| Country: Belgium M&A | 1 of 1 |
| Year: 2011 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2005-06-30 |
Peninsula Pharmaceuticals
Alameda, California, United States Peninsula Pharmaceuticals, Inc. is a pharmaceutical company focuses on licensing, developing, and commercializing anti-infective products for the treatment of life-threatening infections. |
Buy | $245M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-07-15 |
Ortho Dermatologics
Skillman, New Jersey, United States Ortho Dermatologics, Inc. is a provider of dermatologist recommended and prescribed skincare products RETIN-A MICRO, ERTACZO, and RENOVA. |
Sell | $345M |
